Researchers at the Mayo Clinic have developed a blood-based immune profiling approach that may improve the detection of germ cell tumors, the most common form of testicular cancer.
The work, published in the journal Nature Communications, describes a new testing strategy designed to identify cases that can be missed by conventional tumor marker assays.
Testicular cancer most commonly affects adolescents and young adults and is generally highly treatable when diagnosed early. However, standard blood tests can fail to detect disease in cases where tumors do not produce sufficient levels of traditional circulating tumor markers, creating diagnostic blind spots that may delay care.
To address this limitation, the research team developed a method that analyzes thousands of immune system signals in a single blood sample. Using this approach, they created a new assay called GCT-iSIGN.
In a study of 427 blood serum samples, GCT-iSIGN identified 93% of individuals with germ cell tumors and correctly ruled out cancer in 99% of individuals without disease. The test also detected 23 of 24 cases that were missed by standard blood-based tumor marker testing, suggesting potential value as a complementary diagnostic tool in challenging cases.
Improving resolution beyond standard tumor markers
Beyond primary detection, the researchers also developed a second assay, Sem-iSIGN, designed to help distinguish between the two main types of testicular cancer. This distinction is clinically important, as different tumor subtypes may require different treatment strategies and management approaches.
Together, the two assays reflect a broader shift toward immune profiling-based diagnostics that capture a wider range of biological signals than traditional single-analyte tumor marker tests.
The findings build on earlier work from the same research group exploring immune-based biomarkers associated with cancer and related neurologic syndromes, including identification of KLHL11 IgG reported previously in The New England Journal of Medicine.
“When standard blood markers are negative, diagnosis and treatment planning can be delayed,” says Divyanshu Dubey, MBBS, senior and corresponding author of the study and professor of laboratory medicine and pathology and neurology at the Mayo Clinic. “Our findings show a promising path toward a more sensitive blood test approach, but additional studies are needed before it can be used routinely in patient care.”
The study included contributions from co-first authors M. Bakri Hammami, MD, and Andrew M. Knight, PhD. Funding support came from the Department of Defense, and institutional and federal sources.
While the results suggest strong diagnostic performance in study conditions, the authors emphasize that further validation will be required before the tests can be integrated into routine clinical practice. If confirmed, immune profiling approaches such as GCT-iSIGN and Sem-iSIGN could expand the diagnostic toolkit available to clinical laboratories for detecting and characterizing testicular germ cell tumors, particularly in cases where conventional tumor markers fall short.
Note: This news summary was generated by AI based on a published press release, followed by a review from human editors.
